Navigation Links
Rosetta Genomics Announces Exercise and Closing of Underwriter's Over-Allotment Option
Date:8/29/2012

PHILADELPHIA and REHOVOT, Israel, Aug. 29, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced the sale of an additional 825,000 ordinary shares pursuant to the exercise by the underwriter of the over-allotment option granted to the underwriter in connection with Rosetta's recent public offering of 5.5 million ordinary shares at a price to the public of $5.00 per share.  The gross proceeds to Rosetta from the offering, including the exercise of the over-allotment option, were approximately $31.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

A registration statement on Form F-1 relating to the shares was filed with the Securities and Exchange Commission (the "SEC") and was declared effective on August 2, 2012.
A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.
Copies of the final prospectus relating to the offering may be obtained from the offices of Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com, or from the above-mentioned SEC website.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the SEC.  In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.Company Contact:Investor Contacts:Rosetta GenomicsLHAKen Berlin, President & CEOAnne Marie Fields(215) 382-9000 ext. 32(212) 738-3777investors@rosettagenomics.comafields@lhai.comorBruce Voss(310) 691-7100bvoss@lhai.com


'/>"/>
SOURCE Rosetta Genomics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Rosetta Genomics for Its Strategic Excellence and Strong Contribution to Next-Generation Diagnostics
2. Empire Genomics Chooses Funakoshi as Japan Distributor
3. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
4. Gentris Corporation Launches New Pharmacogenomics Services
5. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
6. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
7. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
8. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
9. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... -- Hearing protection devices refer to the barriers that ... inner ear. Hearing protection devices include earplugs, uniform attenuation ... for users exposed to noise levels of over 80 ... are inserted in the ear canal to protect the ... natural sound perception with the help of acoustic filters. ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016  Increasingly, health ... monitoring their vital signs with wireless technology. With the ... can automate patient oversight and remotely detect problems before ... vital signs across in-hospital environments. the ... the United States . --> ...
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism and Related ... autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment ... is key to providing effective treatment for individuals with ASD. Now, over 1,800 ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore Enterprise Cloud, ... move workloads to the cloud. Cirracore provides a secure VMware® vCloud Air ... the Internet. Transformation Solutions (TSL Partners) provides a full range of services ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... therapy products, announced today the introduction of the newly designed, innovative shoulder wrap. ... and better cold therapy coverage for the injured arm and shoulder to promote ...
(Date:2/9/2016)... ... 2016 , ... Shark Finds and Kevin Harrington, and the Product Managers of AsSeenOnTV.pro ... is a newly patented product that has solved some of the basic problems golfers have ... morning dew or right after a rain shower, might understand the struggle of placing the ...
Breaking Medicine News(10 mins):